The effect of anti-CGRP antibody treatment on migraine aura symptoms

The effect of anti-CGRP antibody treatment on migraine aura symptoms - The effect of anti-CGRP antibody treatment on migraine aura symptoms

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044596

Enrollment

200

Registered

2021-06-19

Start date

2021-06-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine with aura

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) The patients who fulfill International Headache Classification 3rd Edition criteria of 1.2 migraine with Aura 2) Patients with visual aura occurring an average of 1 or more times per 3 months over the last one year 3) Inpatients or outpatients 4) Patients with written informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients with secondary headache except for medication overuse headache 2) Patients with trigeminal autonomic cephalalgias (TACs)

Design outcomes

Primary

Measure	Time frame
Changes in visual aura frequency per 3 months after 6 months treatment with Galcanezumab	—

Countries

Japan

Contacts

Public ContactDaisuke DANNO

Tominaga Hospital Headache center, Department of neurology

daisuke_danno@yahoo.co.jp06-6568-1601

Outcome results